Arrowhead reports FY2024 net loss $599.5M; inks Sarepta deal, files plozasiran NDA

ARROWHEAD PHARMACEUTICALS, INC.

2024-FY EPS reported -$5.00 revenue$3,551,000

Net loss of $599.5M (-$5.00 diluted EPS) vs $205.3M loss (-$1.92) in FY2023.
Revenue fell to $3.55M from $240.7M, primarily due to lower collaboration revenue.
Signed licensing deal with Sarepta: $825M upfront ($500M cash, $325M equity), plus $250M over 5 years.
Closed $500M senior secured credit facility with Sixth Street; $400M funded at close.
Submitted NDA for plozasiran (FCS) and received Breakthrough Therapy designation from FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.